Comparison Between 2l vs 3l in HFNC During the Initial Management of Severe Bronchiolitis in Infants (TRAMONTANE2)
Primary Purpose
Bronchiolitis
Status
Unknown status
Phase
Phase 3
Locations
France
Study Type
Interventional
Intervention
treatment by 2l/min/kg in High Flow Nasal cannula (HFNC)
treatment by 3l/min/kg in High Flow Nasal cannula (HFNC)
Sponsored by
About this trial
This is an interventional treatment trial for Bronchiolitis focused on measuring Bronchiolitis, High flow nasal canula
Eligibility Criteria
Inclusion Criteria:
- age < 6 months
- bronchiolitis
- mWCAS > or =3
- hospitalisation: PICU
- signed consent form by parents
Exclusion Criteria:
- Intubated patient
- Neurological or cardiac disease
Sites / Locations
- University hospital of Montpellier
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
treatment by 2l/min/kg in HFNC
treatment by 3l/min/kg in HFNC
Arm Description
treatment by 2l/min/kg in High Flow Nasal cannula (HFNC) during the initial management of severe bronchiolitis in infants (0-6 months years old)
treatment by 3l/min/kg in High Flow Nasal cannula (HFNC) during the initial management of severe bronchiolitis in infants (0-6 months years old)
Outcomes
Primary Outcome Measures
Proportion of failure in both arms
Proportion of failure in both arms during the first 24 hours. Failure criteria: A raise of the Clinical score for respiratory distress (mWCAS) (1 point) or respiratory rate (10/min /H0 and above 60/min) or discomfort (EDIN) (1point /H0 and above 4) or apnea.
Secondary Outcome Measures
assessment of heart rate in both arm
Assessment of the discomfort in both arms with the score of EDIN
assessment of the fraction of inspired oxygen (FiO2) in both arms
FiO2 required to achieve an oxygen saturation between 94 and 97%
number of participants with an aggravation of the clinical score for respiratory distress arms (mWCAS)
Full Information
NCT ID
NCT02824744
First Posted
June 27, 2016
Last Updated
July 1, 2016
Sponsor
University Hospital, Montpellier
1. Study Identification
Unique Protocol Identification Number
NCT02824744
Brief Title
Comparison Between 2l vs 3l in HFNC During the Initial Management of Severe Bronchiolitis in Infants
Acronym
TRAMONTANE2
Official Title
Comparison Between 2l/Min/kg vs 3l/Min/kg in High Flow Nasal Cannula (HFNC) During the Initial Management of Severe Bronchiolitis in Infants
Study Type
Interventional
2. Study Status
Record Verification Date
July 2016
Overall Recruitment Status
Unknown status
Study Start Date
October 2016 (undefined)
Primary Completion Date
October 2017 (Anticipated)
Study Completion Date
October 2017 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Montpellier
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of the study is to evaluate prospectively the clinical benefits of 2 different flow with High flow nasal canula (HFNC: 2l/kg/min) versus (HFNC: 2l/kg/min) in the initial management of bronchiolitis in infants.
Design: Prospective, controlled, randomized, multi-center.
Design: Infants less than 6 month admitted in pediatric intensive care unit for respiratory distress (mWCAS >3) secondary to bronchiolitis but not requiring mechanical ventilation will be randomized in two groups:HFNC "2l/min/kg" or HFNC "3l/min/kg" during 24 hours.
Conditions of measurements:
Primary endpoint: Proportion of failure in both arms during the first 24 hours.
Failure criteria: A raise of the Clinical score for respiratory distress (mWCAS) (1 point) or respiratory rate (10/min /H0 and above 60/min) or discomfort (EDIN) (1point /H0 and above 4) or apnea.
Secondary outcomes: Assessment at H1, H12, H24 of mWCAS, respiratory and heart rate, EDIN score, skin lesions, FiO2 required to achieve an oxygen saturation between 94 and 97%, transcutaneous PCO2 (correlated to an initial gas analysis), Report SpO2 / FiO2
Statistic: Intention to treat Analysis.
Expected number of patients: 135 per arm: 270 children.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bronchiolitis
Keywords
Bronchiolitis, High flow nasal canula
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
270 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
treatment by 2l/min/kg in HFNC
Arm Type
Active Comparator
Arm Description
treatment by 2l/min/kg in High Flow Nasal cannula (HFNC) during the initial management of severe bronchiolitis in infants (0-6 months years old)
Arm Title
treatment by 3l/min/kg in HFNC
Arm Type
Experimental
Arm Description
treatment by 3l/min/kg in High Flow Nasal cannula (HFNC) during the initial management of severe bronchiolitis in infants (0-6 months years old)
Intervention Type
Device
Intervention Name(s)
treatment by 2l/min/kg in High Flow Nasal cannula (HFNC)
Intervention Type
Device
Intervention Name(s)
treatment by 3l/min/kg in High Flow Nasal cannula (HFNC)
Primary Outcome Measure Information:
Title
Proportion of failure in both arms
Description
Proportion of failure in both arms during the first 24 hours. Failure criteria: A raise of the Clinical score for respiratory distress (mWCAS) (1 point) or respiratory rate (10/min /H0 and above 60/min) or discomfort (EDIN) (1point /H0 and above 4) or apnea.
Time Frame
up to 24 hours
Secondary Outcome Measure Information:
Title
assessment of heart rate in both arm
Time Frame
up to 24 hours
Title
Assessment of the discomfort in both arms with the score of EDIN
Time Frame
up to 24 hours
Title
assessment of the fraction of inspired oxygen (FiO2) in both arms
Description
FiO2 required to achieve an oxygen saturation between 94 and 97%
Time Frame
up to 24 hours
Title
number of participants with an aggravation of the clinical score for respiratory distress arms (mWCAS)
Time Frame
up to 24 hours
10. Eligibility
Sex
All
Maximum Age & Unit of Time
6 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
age < 6 months
bronchiolitis
mWCAS > or =3
hospitalisation: PICU
signed consent form by parents
Exclusion Criteria:
Intubated patient
Neurological or cardiac disease
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Christophe MILESI, MD
Phone
+33 4 67336609
Email
c-milesi@chu-montpellier.fr
Facility Information:
Facility Name
University hospital of Montpellier
City
Montpellier
ZIP/Postal Code
34285
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
CHRISTOPHE MILESI, MD
Phone
0033 4 67336609
Email
c-milesi@chu-montpellier.fr
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
All data will be centralized at the sponsor office for the final analysis
Citations:
PubMed Identifier
30343318
Citation
Milesi C, Pierre AF, Deho A, Pouyau R, Liet JM, Guillot C, Guilbert AS, Rambaud J, Millet A, Afanetti M, Guichoux J, Genuini M, Mansir T, Bergounioux J, Michel F, Marcoux MO, Baleine J, Durand S, Durand P, Dauger S, Javouhey E, Leteurtre S, Brissaud O, Renolleau S, Portefaix A, Douillard A, Cambonie G; GFRUP Respiratory Study Group. A multicenter randomized controlled trial of a 3-L/kg/min versus 2-L/kg/min high-flow nasal cannula flow rate in young infants with severe viral bronchiolitis (TRAMONTANE 2). Intensive Care Med. 2018 Nov;44(11):1870-1878. doi: 10.1007/s00134-018-5343-1. Epub 2018 Oct 21.
Results Reference
derived
Learn more about this trial
Comparison Between 2l vs 3l in HFNC During the Initial Management of Severe Bronchiolitis in Infants
We'll reach out to this number within 24 hrs